SRB21

N/A

Report date: 2024/08/01 10:15:41

Base Information

Drug NameSRB21
Drug Alias NameSRB21SRB-21
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Receptor tyrosine-protein kinase erbB-3Anti-HER2
TargetsReceptor tyrosine-protein kinase erbB-3Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSunRock Biopharma SL
China Registration ClassN/A

Develop Information

Active CompaniesDebiopharm GroupSunRock Biopharma SL
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A